Use of aromatase inhibitors for endometrial thinning in preparation for surgical procedures on the endometrial cavity and uterus
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 28, 2014
Issued Date -
N/A
app pub date -
Oct 4, 2005
filing date -
Oct 4, 2004
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Aromatase inhibitors are administered to a female patient prior to endometrial ablation or resection procedures in order to thin the endometrium to a thickness of less than 6 mm, and preferably less than 4 mm, so as to enhance the treatment outcome. Of course, administration of aromatase inhibitors would be useful for other surgical procedures on the endometrial cavity and the uterus. Commercially available aromatase inhibitors, including, the nonsteroidal preparations, anastrozole and letrozole, and a steroidal agent, exemestane, are well-tolerated, and have been shown to decrease serum estrogen levels. The aromatase inhibitor can be used alone, or in combination with other aromatase inhibitors or pharmaceutical agents, such as hormones.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully